Compugen Ltd. (CGEN)
After hours:
| Previous close | 2.1600 |
| Open | 2.2200 |
| Bid | 2.1000 x 200 |
| Ask | 2.1300 x 100 |
| Day's range | 2.0650 - 2.2200 |
| 52-week range | 0.5300 - 3.0300 |
| Volume | |
| Avg. volume | 498,904 |
| Market cap | 188.909M |
| Beta (5Y monthly) | 2.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
Simply Wall St.We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Compugen...
PR NewswireCompugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.
PR NewswireCompugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for
